Drug Trial News

RSS

Positive results from Anacor’s second of two Phase 3 trials of tavaborole for onychomycosis

Anacor Pharmaceuticals today announced positive preliminary results from the second of two Phase 3 trials of tavaborole (known as Study 302).

28 Feb 2013

TikoMed, BRI partner to investigate IBsolvMIR in phase II trial for chronic pancreatitis

Baylor Research Institute (BRI), the research arm of Baylor Health Care System, and TikoMed AB announced today that an agreement has been established to investigate TikoMed´s product IBsolvMIR® in a phase II clinical trial.

28 Feb 2013

Starch-based intravenous fluids cause unnecessary deaths in seriously ill patients

Starch-based intravenous (IV) fluids used by the NHS to treat seriously ill patients are causing unnecessary deaths, according to a new Cochrane systematic review by researchers at the London School of Hygiene & Tropical Medicine.

28 Feb 2013

Long-term treatment with spironolactone improves left ventricular diastolic function in HF patients

Among patients with heart failure with preserved ejection fraction, long-term treatment with the medication spironolactone improved left ventricular diastolic function but did not affect maximal exercise capacity, patient symptoms, or quality of life, according to a study appearing in the February 27 issue of JAMA.

28 Feb 2013

Resolve Therapeutics, Takeda partner to develop compounds for treatment of lupus

Takeda Pharmaceutical Company Limited and Resolve Therapeutics, LLC today jointly announced that they have entered into a partnership to develop compounds for the treatment of lupus (also known as Systemic Lupus Erythematosus, or SLE) and other autoimmune diseases.

27 Feb 2013

Inviragen to initiate second stage of DENVax Phase 2 study in dengue

Inviragen, Inc. today announced the initiation of the second stage of an ongoing Phase 2, randomized, double-blind, placebo-controlled study of DENVax, the Company's investigational dengue vaccine.

27 Feb 2013

Ampio Pharmaceuticals starts Optina clinical trial

Ampio Pharmaceuticals, Inc. announced oral dosing of the first patient in a 505(b)(2) clinical trial of the investigational drug Optina in diabetic macular edema.

27 Feb 2013

Omega-3 fish oils could help protect against skin cancer

Taking omega-3 fish oils could help to protect against skin cancer, according to researchers at The University of Manchester.

27 Feb 2013

High-level results from AstraZeneca’s naloxegol Phase III trial on opioid-induced constipation

AstraZeneca today announced high-level results from KODIAC-08, an open-label, randomised, 52-week, long-term safety trial of naloxegol versus usual care (UC) in patients with non-cancer related pain and opioid-induced constipation (OIC). UC was defined as the investigator's choice of an existing laxative treatment regimen for OIC.

26 Feb 2013

DHA supplementation during pregnancy reduces very low birth weight and early preterm delivery

University of Kansas researchers have found that the infants of mothers who were given 600 milligrams of the omega-3 fatty acid DHA during pregnancy weighed more at birth and were less likely to be very low birth weight and born before 34 weeks gestation than infants of mothers who were given a placebo. This result greatly strengthens the case for using the dietary supplement during pregnancy.

26 Feb 2013

N-acetylcysteine improves graft survival following liver transplantation

Researchers from Italy have found that the antioxidant, N-acetylcysteine (NAC), when injected prior to harvesting of the liver, significantly improves graft survival following transplantation.

26 Feb 2013

Adynxx initiates AYX1 Phase 2 study to prevent post-surgical pain

Adynxx, a clinical-stage pharmaceutical company developing a first-in-class platform of therapeutics to address pain at its molecular roots, announced today that the first patient was dosed in a Phase 2 study of its lead investigational drug candidate for the prevention of post-surgical pain, AYX1.

26 Feb 2013

Avaxia initiates AVX-470 Phase 1b clinical study in ulcerative colitis

Avaxia Biologics, Inc., a clinical-stage biopharmaceutical company developing gut-targeted therapeutics, announced today that the first patient has been dosed in a Phase 1b clinical study of AVX-470, an oral anti-TNF antibody, for the treatment of ulcerative colitis.

25 Feb 2013

Researchers to present new results for Merck's allergy immunotherapy tablets at AAAAI meeting

Merck, known as MSD outside the United States and Canada, today announced that researchers will present new data analyses of the safety and efficacy of the company's investigational allergy immunotherapy tablets (AITs) for ragweed pollen (Ambrosia artemisiifolia) and grass pollen (Phleum pratense) at the 2013 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting.

25 Feb 2013

Non-surgical weight loss device clinical trial completes enrollment

ReShape Medical® Inc announced today that it has completed enrollment in the pivotal clinical trial for the ReShape Duo® Intragastric Balloon, one of the first non-surgical weight loss devices developed for the U.S. market.

25 Feb 2013

Circassia announces results from ToleroMune cat allergy phase II clinical study

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced the results of a phase II clinical study showing that a short course of just four doses of its ToleroMune cat allergy therapy maintained improvements in patients' symptoms two years after the start of treatment.

25 Feb 2013

Omalizumab fast, safe and well-tolerated in teens and adults with chronic spontaneous urticaria

An international team of researchers has found that a once-a-month, high-dose injection of a commonly used asthma drug is highly effective in treating teens and adults chronically afflicted with hives and severe, itchy rash. The drug, omalizumab, was tested on 323 people at 55 medical centers for whom standard antihistamine therapy failed to quell their underlying, allergy-like reaction, known as chronic idiopathic urticaria or chronic spontaneous urticaria.

25 Feb 2013

Drug Trial News

Positive results from Anacor’s second of two Phase 3 trials of tavaborole for onychomycosis

TikoMed, BRI partner to investigate IBsolvMIR in phase II trial for chronic pancreatitis

Starch-based intravenous fluids cause unnecessary deaths in seriously ill patients

Long-term treatment with spironolactone improves left ventricular diastolic function in HF patients

Resolve Therapeutics, Takeda partner to develop compounds for treatment of lupus

Inviragen to initiate second stage of DENVax Phase 2 study in dengue

Ampio Pharmaceuticals starts Optina clinical trial

Omega-3 fish oils could help protect against skin cancer

High-level results from AstraZeneca’s naloxegol Phase III trial on opioid-induced constipation

DHA supplementation during pregnancy reduces very low birth weight and early preterm delivery

N-acetylcysteine improves graft survival following liver transplantation

Adynxx initiates AYX1 Phase 2 study to prevent post-surgical pain

Avaxia initiates AVX-470 Phase 1b clinical study in ulcerative colitis

Researchers to present new results for Merck's allergy immunotherapy tablets at AAAAI meeting

Non-surgical weight loss device clinical trial completes enrollment

Circassia announces results from ToleroMune cat allergy phase II clinical study

Omalizumab fast, safe and well-tolerated in teens and adults with chronic spontaneous urticaria

Ampio to initiate dose escalation run-in study for treatment of knee osteoarthritis

Okairos to commence novel RSV vaccine Phase I clinical trial

New, effective and less toxic therapeutic option for patients with HER2-positive breast cancer

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News